SCHEDULE 13G/A: BML Investment Partners and Braden Michael Leonard Disclose Significant Passive Stake in Athira Pharma
Beneficial Ownership Report
BML Investment Partners, L.P. and Leonard Braden Michael have filed an amended Schedule 13G, reporting a combined passive beneficial ownership of 6.5% of Athira Pharma Inc.'s common stock as of December 31, 2024.
Summary
- BML Investment Partners, L.P. and Leonard Braden Michael have filed an Amendment No. 1 to Schedule 13G regarding their beneficial ownership in Athira Pharma Inc.
- As of December 31, 2024, Leonard Braden Michael beneficially owns an aggregate of 2,484,445 shares of Athira Pharma Inc. common stock, representing 6.5% of the class.
- BML Investment Partners, L.P. beneficially owns 2,233,167 shares, representing 5.8% of the class.
- Leonard Braden Michael holds sole voting and dispositive power over 251,278 shares and shared voting and dispositive power over 2,233,167 shares.
- BML Investment Partners, L.P. holds shared voting and dispositive power over 2,233,167 shares.
- The filing indicates a passive investment intent, stating the securities were not acquired or held for the purpose of changing or influencing control of the issuer.
Sentiment
Score: 5
Explanation: The document is a factual disclosure of beneficial ownership, indicating a passive investment. It does not contain information that would inherently be considered positive or negative regarding the company's operational performance or future prospects.
Future Outlook
NA
Industry Context
This Schedule 13G filing is a disclosure of beneficial ownership by specific investors in Athira Pharma Inc. and does not provide broader industry trends or context.
Stakeholder Impact
- Shareholders: Provides transparency regarding significant ownership stakes, potentially signaling confidence from large investors (though passive).
Key Dates
| Date | Description |
|---|---|
| 12/31/2024 | Date of event requiring the filing of this statement. |
| 02/14/2025 | Date of filing and signature. |
Keywords
Athira Pharma Inc., BML Investment Partners, Leonard Braden Michael, Schedule 13G, beneficial ownership, common stock, passive investment, SEC filing, pharmaceutical, biotechnology
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.